BTK inhibition has shown remarkable activity across B-cell histologies and has promise to be used as a single drug therapy for MM patients in certain circumstances due to its efficacy and lack of toxicity [39,65,71]. The gene discussed is BTK; the disease is Miyoshi myopathy.